Skip to content
10-K

Annual Report

Acorda Therapeutics, Inc.

0000950170-24-039464

← back to feed
Filed
Apr 1, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2023 · Dec 31, 2023 1.24M sh
Shares Diluted restated FY 2023 · Dec 31, 2022 1.01M sh
Capex FY 2023 · Dec 31, 2023 $264K
Capex FY 2023 · Dec 31, 2022 $136K
Operating Cash Flow FY 2023 · Dec 31, 2023 −$13.98M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$20.92M
Cash And Equivalents FY 2023 · Dec 31, 2023 $29.98M
Cash And Equivalents FY 2023 · Dec 31, 2022 $37.54M
Cash And Equivalents FY 2023 · Dec 31, 2021 $45.63M
Stockholders Equity FY 2023 · Dec 31, 2023 −$157.96M
Stockholders Equity FY 2023 · Dec 31, 2022 $93.62M
Current Liabilities FY 2023 · Dec 31, 2023 $227.77M
Current Liabilities FY 2023 · Dec 31, 2022 $37.95M
Current Assets FY 2023 · Dec 31, 2023 $74.79M
Current Assets FY 2023 · Dec 31, 2022 $82.12M
Total Assets FY 2023 · Dec 31, 2023 $108.53M
Total Assets FY 2023 · Dec 31, 2022 $395.6M
Eps Diluted FY 2023 · Dec 31, 2023 −$203.57
Eps Diluted restated FY 2023 · Dec 31, 2022 −$65.23
Eps Basic FY 2023 · Dec 31, 2023 −$203.57
Eps Basic restated FY 2023 · Dec 31, 2022 −$65.23
Sga Expense FY 2023 · Dec 31, 2023 $89.7M
Sga Expense FY 2023 · Dec 31, 2022 $106.26M
Rd Expense FY 2023 · Dec 31, 2023 $5.15M
Rd Expense FY 2023 · Dec 31, 2022 $5.8M
Net Income FY 2023 · Dec 31, 2023 −$252.85M
Net Income FY 2023 · Dec 31, 2022 −$65.92M
Operating Income FY 2023 · Dec 31, 2023 −$264.95M
Operating Income FY 2023 · Dec 31, 2022 −$35.34M
Cost Of Revenue FY 2023 · Dec 31, 2023 $15.28M
Cost Of Revenue FY 2023 · Dec 31, 2022 $30.33M
Revenue FY 2023 · Dec 31, 2023 $117.63M
Revenue FY 2023 · Dec 31, 2022 $118.57M